biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 5
- Drugs
- 16
- Patents
- 27
NEUROCRINE BIOSCIENCES projects
5 ClinicalTrials.gov programs sponsored by NEUROCRINE BIOSCIENCES.
NEUROCRINE BIOSCIENCES has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
NBI-1117568
NEUROCRINE BIOSCIENCES INC
Schizophrenia
5 trials -
NBI-98854-ATS3019
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
Placebo
NEUROCRINE BIOSCIENCES INC
Schizophrenia
2 trials -
Luvadaxistat
NEUROCRINE BIOSCIENCES INC
Schizophrenia
2 trials -
Valbenazine
NEUROCRINE BIOSCIENCES INC
Schizophrenia
3 trials
Frequently asked questions
How many clinical projects does NEUROCRINE BIOSCIENCES have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.